Abstract
Breathlessness is a complex symptom, incorporating physical and emotional components. After considering the control of respiration, the causes of breathlessness and mechanisms in chronic lung disease are described. The assessment of the breathlessness patient can include symptom scoring, measures of the impact on life, descriptors of the sensation and functional measures. Management is initially by disease modification of the underlying process, but alongside this, pharmacological and non-pharmacological interventions may be included. The principal drugs employed are opioids and benzodiazepines. There are a variety of non-drug interventions that are used for dyspnea in lung disease, some including an exercise component, some not. Oxygen also has a role in the hypoxemic patient. The presence of breathlessness can also have prognostic significance in advanced lung disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American Thoracic Society. Dyspnea, mechanisms, assessment and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321–40.
El-Manshawi A, Killian KJ, Summers E, Jones NL. Breathlessness during exercise with and without resistive loading. J Appl Physiol. 1986;61:896–905.
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31:58–69.
Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. 2001;21:95–102.
Kozu R, Jenkins S, Senjyu H. Characteristics and disability in individuals with idiopathic pulmonary fibrosis (IPF) stratified by medical research council (MRC) dyspnoea grade. Respirology. 2011;16:1323–9.
Fairburn AJ, Wood CH, Fletcher CM. Variability in answers to a questionnaire on respiratory symptoms. Br J Prev Soc Med. 1959;13:175–93.
Dorman S, Jolley C, Abernethy A, et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med. 2009;23:213–27.
Mahler D. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:234–8.
Wilcock A, Crosby V, Hughes A, et al. Descriptors of breathlessness in patients with cancer and other cardiorespiratory diseases. J Pain Symptom Manage. 2002;23:182–9.
Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care. 1998;7:200–4.
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–8.
American Thoracic Society. ATS statement: guidelines for six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.
Wilcock A, Crosby D, Clarke D, Corcoran R, Tattersfield A. Reading numbers aloud – a measure of the limiting effect of breathlessness in patients with cancer. Thorax. 1999;54:1099–103.
Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–44.
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327:523–6.
Currow DC, McDonald C, Oaten S, et al. Once daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42:388–99.
Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced disease in adults. Cochrane Database Syst Rev. 2010;(1).DOI:10.1002/14652858.CD007354.pub2.
Bausewein C, Booth S, Gysels M, Higginson IJ. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases (review). The Cochrane Library 2009;(3). DOI:10.1002/14651858.CD005623.pub2.
Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomised controlled, crossover trial. J Pain Symptom Manage. 2010;39:831–8.
Corner J, Plant H, A’Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med. 1996;10:299–305.
Bredin M, Corner J, Krishnasamy M, et al. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. Br Med J. 1999;318:901–4.
Connors S, Graham S, Peel T. An evaluation of a physiotherapy-led non-pharmacological breathlessness programme for patients with intrathoracic malignancy. Palliat Med. 2007;21:285–7.
Wood H, Connors S, Dogan S, Peel T. Individual experiences and impacts of a physiotherapist-led, non-pharmacological, breathlessness programme for patients with intrathoracic malignancy – a qualitative study. Palliat Med. 2012. doi:10.177/0269216312464093. Accessed 5 Nov 2012.
British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. Thorax. 2001;56:827–34.
Donner CF, Muir JF. Rehabilitation and Chronic Care Scientific Group of the European Respiratory Society. Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Eur Respir J. 1997;10:744–57.
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Review. 2009; Cochrane Collaboration. DOI:10.1002/16511858.CD003793.pub2.
Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double–blind, randomised controlled trial. Lancet. 2010;376:784–93.
Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care. 2003;1:337–44.
Pashall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society Statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:432–52.
Prognostic Indicator Guidance (PIG). 4th ed. 2011.www.goldstandardsframework.org.uk. Accessed 1 Apr 2012.
Celli BR, Cote CG, Marin JM, et al. The Body-mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–11.
Vigano A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med. 2000;14:363–74.
Marie Curie Palliative Care Institute. Liverpool care pathway for the dying patient. 2009.http://www.liv.ac.uk/mcpcil/liverpool-care-pathway/. Accessed 1 Apr 2012.
Edmonds P, Higginson I, Altmann D, Sen-gupta G, McDonnell M. Is the presence of dyspnea a risk factor for morbidity in cancer patients? J Pain Symptom Manage. 2000;19:15–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Peel, E.T., Burns, G.P. (2013). Breathlessness. In: Bourke, S., Peel, E. (eds) Integrated Palliative Care of Respiratory Disease. Springer, London. https://doi.org/10.1007/978-1-4471-2230-2_2
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2230-2_2
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2229-6
Online ISBN: 978-1-4471-2230-2
eBook Packages: MedicineMedicine (R0)